
In today’s briefing:
- Sanil Electric Poised for Pop on Nov 20 KOSPI200 Ad‑Hoc (HD Hyundai Merger)
- SK Square: Selling Its Stake in 11st to SK Planet
- SK Hynix Q325. HBM, DRAM, NAND All Sold Out Through 2026
- Primer: SK Hynix (000660 KS) – Oct 2025
- Primer: SK Square (402340 KS) – Oct 2025
- Primer: Neopharm Co Ltd (092730 KS) – Oct 2025
- Samsung Biologics (207940 KS): Momentum Accelerates in 3Q; Solid Order Book; Reaffirms FY Guidance

Sanil Electric Poised for Pop on Nov 20 KOSPI200 Ad‑Hoc (HD Hyundai Merger)
- HD Hyundai merger: both legs in index, Mipo delists, slot opens — one new name gets added to KOSPI200 via ad‑hoc.
- Sanil Electric (062040 KS) to replace HD Mipo pre‑Dec review. If DTV settles back into the 500–600k range, then KS200 ETFs will need to scoop ~0.3–0.4x DTV on Nov 26.
- Better to front‑run KRX; with AI power trade still hot, Nov 20 announcement likely sparks outsized price action vs waiting for rebalance print.
SK Square: Selling Its Stake in 11st to SK Planet
- On 29 October, SK Square announced that it is selling its stake in 11st to SK Planet. This is likely to have a slightly negative impact on SK Square.
- Given SK Planet’s limited financial resources, it is likely that SK Square will provide funding to SK Planet through a capital increase.
- However, the biggest factor driving SK Square’s share price right now is the continued surge in SK Hynix’s share price.
SK Hynix Q325. HBM, DRAM, NAND All Sold Out Through 2026
- SK Hynix reported Q325 revenues of ₩34.45 trillion, up +10% QoQ and up 39% YoY representing an all time quarterly revenue record
- Now given the customers demand and the company’s capacity for next year not only HBM but DRAM and NAND capacity has essentially been sold out.
- DRAM margin could rise closer to HBM but the company does not plan to immediately adjust the capacity mix based on what can be a short-lived change in profitability
Primer: SK Hynix (000660 KS) – Oct 2025
- SK Hynix is exceptionally well-positioned to capitalize on the artificial intelligence supercycle, driven by its market-leading position in High Bandwidth Memory (HBM), a critical component for AI accelerators.
- The company is experiencing a period of record financial performance, with surging revenue and profitability fueled by insatiable HBM demand and a broader recovery in the DRAM and NAND markets.
- While facing intensified competition from rivals Samsung and Micron, SK Hynix is aggressively investing in next-generation technologies (HBM4, AI-NAND) and expanding production capacity to solidify its competitive advantages and meet future demand.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Primer: SK Square (402340 KS) – Oct 2025
- SK Square is a South Korean investment holding company, spun off from SK Telecom in 2021, with a strategic focus on the semiconductor and information and communication technology (ICT) sectors.
- The company’s intrinsic value and performance are overwhelmingly tied to its cornerstone asset, a significant ~20% stake in SK Hynix, a global leader in the memory semiconductor market.
- Future value creation is expected to be driven by the performance of SK Hynix, the potential narrowing of its substantial Net Asset Value (NAV) discount, and strategic investments in new growth areas, though it faces high volatility from the semiconductor industry.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Primer: Neopharm Co Ltd (092730 KS) – Oct 2025
- Proprietary Technology Driving Brand Strength: Neopharm’s core competitive advantage lies in its patented Multi-Lamellar Emulsion (MLE) technology, which mimics the natural lipid structure of the skin. This scientifically-backed technology underpins its key brands like Atopalm and Real Barrier, fostering strong brand loyalty, particularly in the sensitive and dry skin segments.
- Favorable Industry Tailwinds: The global dermo-cosmetics market is experiencing robust growth, with forecasts projecting a CAGR of 7.4% to 11.1%. This expansion is driven by rising consumer awareness of skin health, an increasing prevalence of skin conditions, and a growing demand for scientifically-backed, therapeutic cosmetic solutions.
- Solid Financials and Shareholder Returns: The company has demonstrated a strong track record of revenue and net income growth over the past decade. This financial strength is complemented by a commitment to shareholder returns, evidenced by a consistently increasing dividend per share and a dividend yield that has grown significantly over the last three years.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Samsung Biologics (207940 KS): Momentum Accelerates in 3Q; Solid Order Book; Reaffirms FY Guidance
- Samsung Biologics (207940 KS) reported revenue of KRW1,660B (up 40% YoY and 29% QoQ) and operating profit of KRW729B (up 115% YoY and 53% QoQ) in 3Q25.
- In 3Q25, the company continued to secure new manufacturing and development contracts with global pharmaceutical partners, bringing its cumulative contract volume to over $20B since its founding.
- Amid steady client demand and efficient capacity utilization, Samsung Biologics is confident on achieving full-year revenue growth guidance of 25–30% YoY, as revised upward in last quarter.